Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

被引:16
|
作者
Daniels, Molly S. [1 ]
Urbauer, Diana L. [2 ]
Stanley, Jennifer L. [1 ]
Johnson, Kristin G. [3 ]
Lu, Karen H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77230 USA
关键词
BRCA1; BRCA2; genetic testing; ovarian cancer; cancer recurrence; NONPOLYPOSIS COLORECTAL-CANCER; BRCA2; MUTATIONS; DNA-REPAIR; SURVIVAL; SUSCEPTIBILITY; PREVALENCE; POLYMERASE; INHIBITORS; CARCINOMA; FEATURES;
D O I
10.1097/GIM.0b013e3181ab2295
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To determine when, in reference to the course of their treatment. women with ovarian cancer are seen for genetic Counseling. as well as to determine what factors influence this timing. Methods: Single institution retrospective chart review of patients with ovarian cancer Who Underwent BRCA1/BRCA2 genetic testing. Results: Thirty-three percent of our sample (n = 100) were seen for genetic counseling after ovarian cancer recurrence. In four cases, genetic test results were disclosed to next of kin. Thirty percent of women seen for genetic counseling after recurrence received their initial treatment elsewhere. Women with a history of breast cancer were significantly more likely to be seen for genetic counseling at an earlier phase of their treatment than women with no history of breast cancer. Conclusion: We found that one third of patients with ovarian cancer who underwent genetic testing were seen for initial genetic counseling after disease recurrence. In some cases, genetic counseling took place during the end of life care. with genetic test results disclosed to next of kin. Given the poor prognosis of women with recurrent ovarian cancer, we advocate providing genetic Counseling at the time of initial ovarian cancer treatment both in comprehensive cancer centers and in community oncology settings. Genet Med 2009:11(9):624-628.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 50 条
  • [41] Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
    Pietragalla, Antonella
    Arcieri, Martina
    Marchetti, Claudia
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1803 - 1810
  • [42] Psychosocial Aspects of Mainstreaming Genetic Counselling for Genetic Testing of BRCA1 and BRCA2 in Ovarian Cancer Patients in Malaysia (MaGiC)
    Wong, Siu Wan
    Bashah, Nor Syuhada Ahmad
    Mariapun, Shivaani
    Hassan, Nur Tiara
    Padmanabhan, Heamanthaa
    Lim, Joanna Mei Ch'wan
    Thong, Meow Keong
    Woo, Yin Ling
    Bleiker, Eveline
    Yoon, Sook-Yee
    PSYCHO-ONCOLOGY, 2018, 27 : 139 - 140
  • [43] BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer
    Gross, Amy L.
    Blot, William J.
    Visvanathan, Kala
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (06): : 597 - 598
  • [44] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [45] Genetic predisposition to breast and ovarian cancer. An update on the BRCA1 and BRCA2 genes
    Santarosa, M
    Viel, A
    Boiocchi, M
    MINERVA BIOTECNOLOGICA, 1999, 11 (01) : 7 - 16
  • [46] BRCA1 and BRCA2 alterations in ovarian MMMT
    Geisler, JP
    Goodheart, MJ
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 774 - 774
  • [47] Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: A trend over time
    Meyer, L. A.
    Anderson, M. E.
    Lacour, R. A.
    Westin, S. N.
    Burzawa, J. K.
    Urbauer, D. L.
    Daniels, M. S.
    Burke, C. C.
    Gershenson, D. M.
    Lu, K. H.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S96 - S97
  • [48] BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
    Moslehi, R
    Chu, W
    Karlan, B
    Fishman, D
    Risch, H
    Fields, A
    Smotkin, D
    Ben-David, Y
    Rosenblatt, J
    Russo, D
    Schwartz, P
    Tung, N
    Warner, E
    Rosen, B
    Friedman, J
    Brunet, JS
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (04) : 1259 - 1272
  • [49] Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    McCuaig, Jeanna M.
    Karlan, Beth Y.
    Eisen, Andrea
    Tung, Nadine
    Bordeleau, Louise
    Senter, Leigha
    Eng, Charis
    Couch, Fergus
    Fruscio, Robert
    Weitzel, Jeffrey N.
    Olopade, Olufunmilayo
    Singer, Christian F.
    Pal, Tuya
    Foulkes, William D.
    Neuhausen, Susan L.
    Sun, Ping
    Lubinski, Jan
    Narod, Steven A.
    Huzarski, Tomasz
    Cybulski, Cezary
    Rosen, Barry
    Sweet, Kevin
    Zakalik, Dana
    Wood, Marie
    McKinnon, Wendy
    Elser, Christine
    Wiesner, Georgia
    Friedman, Eitan
    Meschino, Wendy
    Snyder, Carrie
    Metcalfe, Kelly
    Poll, Aletta
    Warner, Ellen
    Kim, Raymond
    Armel, Susan
    Demsky, Rochelle
    Ainsworth, Peter
    Steele, Linda
    Saal, Howard
    Serfas, Kim
    Panchal, Seema
    Cullinane, Carey A.
    Reilly, Robert E.
    Blum, Joanne L.
    Kwong, Ava
    Rayson, Daniel
    Ramon y Cajal, Teresa
    Dungan, Jeffrey
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 820 - 826
  • [50] OVARIAN CANCER SCREENING BY AUSTRALIAN WOMEN FROM FAMILIES WITH BRCA1 OR BRCA2 MUTATIONS
    Wuttke, M.
    Milne, R.
    Weideman, P.
    Picken, S.
    Smith, C.
    Friedlander, M.
    McLachlan, S.
    Hopper, J. L.
    Phillips, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 223 - 224